The planned Phase 2a study will assess safety and how oral blarcamesine moves through the body in adult men; the drug remains ...

Edesa Biotech, Inc. reported that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application for its Phase 2 clinical study of EB06 in vitiligo, ...

Bank of America's $1.2B anti-money laundering fine masked strong core earnings of $1.08/share (vs. $1.10 expected) in Q3.

VKTX launches two phase III studies of oral VK2735 for obesity, building on phase II results showing up to 12.2% mean weight ...

Harris County needs more than justices of the peace who are content with merely speeding along cases in Harris County’s ...

First patient dosed in global Phase 2 study evaluating VVD-214, an oral Werner helicase (WRN) inhibitor, plus pembrolizumab ...

Subgroup analysis of patients who received Bruton Tyrosine Kinase inhibitor (BTKi) treatment immediately prior to iopofosine I 131 achieved 87.5% ...

VK2735 is the company's investigational dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors and is being developed in both oral and ...

SUNRISE -1 and SUNRISE-2 Studies to Evaluate Oral VK2735 in Obese Adults with and without Type 2 Diabetes. SAN DIEGO, Oct. 14, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viki ...

Viking Therapeutics, Inc. announced the initiation of the SUNRISE Phase 3 clinical program for oral VK2735, the company's (GLP-1) and g ...

The phase 2 EVITA trial (NCT03682029) was the first double-blind, randomized, placebo-controlled study of oral vitamin C in ...

A systematic scoping review of 81 randomized controlled trials published since 2013 finds that psychological treatment ...